Nanogen Pharmaceutical Biotechnology Joint Stock Company

What Nanogen Pharmaceutical Biotechnology Joint Stock Company does

Nanogen Pharmaceutical Biotechnology Joint Stock Company is a Vietnamese biopharmaceutical manufacturer founded in 1997 and headquartered in Ho Chi Minh City's Saigon Hi-tech Park. The company applies recombinant DNA and protein technology using Chinese Hamster Ovary (CHO) cell lines to develop and produce therapeutic proteins, biosimilars, and vaccines. Its commercial portfolio includes hepatitis B and C treatments (Feronsure, Pegnano), neutropenia therapies for chemotherapy patients (Ficocyte, Pegcyte), anemia therapy for chronic kidney disease (Nanokine), intravenous solutions, over-the-counter and chemical drugs, and active pharmaceutical ingredients (APIs). Nanogen gained regional prominence through Nanocovax, Vietnam's first domestically developed COVID-19 vaccine, which advanced through Phase 1/2 clinical trials with reported 99.4% seroconversion and 100% safety, and received Ministry of Health approval for a 13,000-volunteer Phase 3 trial in June 2021.

The company holds three granted US patents covering PEG-interferon lambda 1 conjugates for hepatitis treatment and a chemically defined glycosylation-enhancer cell culture medium for CHO cell culture. It operates four manufacturing facilities totaling approximately 73,000 m2 (three in Ho Chi Minh City and one in Lam Dong Province), with over $50 million invested in R&D and production infrastructure and a planned capacity of 50–100 million vaccine doses annually. Nanogen also offers Contract Manufacturing Organization (CMO) services and generates licensing income through gene technology transfers to international pharmaceutical and cosmetic companies.

Nanogen sells primarily through direct supply to Vietnamese hospitals and healthcare providers, holding over 80% domestic market share in hepatitis B and C treatments. Internationally, products are exported to more than 10 countries across Asia, EMEA, Africa, and South America. Pricing is positioned 50–67% below imported equivalents, leveraging Vietnam-based manufacturing cost advantages. Key clinical and academic partners include the Military Medical Academy, Pasteur Institute Ho Chi Minh City, and Hanoi University of Pharmacy, with technical and clinical advisory support from Prof. Harvey F. Lodish and Dr. Robert G. Gish.

Name

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Legal name

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Website

https://nanogenpharma.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

251–500 employees

Short description

Nanogen is a Vietnamese biopharmaceutical company founded in 1997 that develops and manufactures recombinant protein therapeutics, biosimilars, and vaccines using CHO cell-based technology, supplying Vietnamese hospitals with over 80% hepatitis market share and exporting to 10+ countries.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Biopharmaceutical products
• Recombinant protein technology
• Hepatitis treatments
• Biosimilar manufacturing
• Vaccine development

Headquarters

HQ city

Ho Chi Minh City

HQ country

Vietnam

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Nanogen generates revenue primarily from manufacturing and selling biopharmaceutical products including treatments for hepatitis B, hepatitis C, anemia, cancer, and other conditions. Products include Feronsure, Pegnano, Ficocyte, Pegcyte, Nanokine, and biosimilars. The company holds over 80% domestic market share in hepatitis treatments in Vietnam.
2. CMO (Contract Manufacturing Organization) Services: Nanogen offers CMO services providing manufacturing capabilities to other pharmaceutical companies for production of biopharmaceutical products.
3. Technology Transfer and Licensing: Nanogen generates revenue through technology transfers and gene technology licensing to international pharmaceutical and cosmetic companies. Examples include anti-aging gene technology transferred to a French cosmetics company, diabetes treatment gene to an Indian pharmaceutical company, and cardiovascular treatment gene to a Swiss pharmaceutical company.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Nanogen manufactures and sells biopharmaceutical products developed through proprietary recombinant DNA/protein technology using CHO (Chinese Hamster Ovary) cells. The company's portfolio includes treatments for hepatitis B, hepatitis C, chronic kidney disease-related anemia, cancer supportive care, I.V. solutions, biosimilars, and the Nanocovax COVID-19 vaccine. The company also provides CMO (Contract Manufacturing Organization) services and generates revenue through technology transfer and gene technology licensing to international pharmaceutical companies.

Product overview

Nanogen Pharmaceutical Biotechnology Joint Stock Company is a Vietnamese biotech pharmaceutical company offering a diverse portfolio of products and services. The company manufactures Active Pharmaceutical Ingredients (API) and finished pharmaceutical products including Biosimilars, I.V. Solutions, OTC Products, and Chemical Drugs. Key therapeutic products include Feronsure (hepatitis B/C treatment), Pegnano, Ficocyte, Pegcyte (neutropenia treatment), and Nanokine (anemia treatment). The company gained prominence with Nanocovax, Vietnam's first domestically developed Covid-19 vaccine using recombinant protein technology. Nanogen also offers CMO (Contract Manufacturing Organization) services and has pipeline products including anti-cancer monoclonal antibodies (Trastuzumab, Bevacizumab, Rituximab).

Differentiator

Problem solved

Functional benefit

Products and services

• Nanocovax COVID-19 vaccine developed using recombinant protein technology with CHO cells to produce spike protein S antigen. The first Vietnamese COVID-19 vaccine to complete preclinical and enter clinical trials, with 99.4% seroconversion rate in Phase 2 and 96.87-100% neutralization response to Wuhan strain.
• Active Pharmaceutical Ingredient (API) Pharmaceutical raw materials and active ingredients manufactured using recombinant DNA/protein technology for various therapeutic applications.
• Biosimilars Biosimilar products developed through biotechnology methods for treatment of various diseases including hepatitis, anemia, and cancer supportive care.
• Feronsure Treatment for hepatitis B and C, produced using recombinant DNA technology. Priced significantly lower than imported alternatives at 200,000 VND per 3 doses per week versus 600,000-1,500,000 VND per dose for imported versions.
• Pegnano Pegylated interferon product for hepatitis B and C treatment.
• Ficocyte Product to reduce neutropenia in patients treated with cytotoxic chemotherapy for malignancy.
• Pegcyte Pegylated product for reducing neutropenia in cancer patients undergoing chemotherapy.
• Nanokine Treatment for anemia caused by kidney failure.
• I.V. Solutions

Quantifiable outcome

• 99.4% seroconversion rate in Phase 2 clinical trials
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• Hanoi University of PharmacycoreStrategic or Co-development Partner · 30 November 2020Cooperation agreement signed for staff training, scientific research, drug R&D, and cooperation in science and technology services. Nanogen committed to supporting the university in developing pharmaceutical expertise and research capabilities.
• Military Medical Academy (Vietnam)coreStrategic or Co-development PartnerPrimary research partner for Phase 1, 2, and 3 clinical trials of Nanocovax vaccine. Responsible for Northern Vietnam trial sites including Military Hospital 103 and Hung Yen Provincial Preventive Medicine Center.
• Pasteur Institute Ho Chi Minh CitycoreStrategic or Co-development PartnerLead research partner for Phase 2 and 3 clinical trials in Southern Vietnam. Conducted trials at Ben Luc District Medical Center, Long An Province, and planned sites in My Tho and Cho Gao.
• Military Insurance Company (MIC)supportingOthersInsurance partner providing clinical trial liability insurance for volunteers participating in Nanocovax COVID-19 vaccine clinical trials. Signed insurance contract on December 16, 2020.
• Lac Viet Pharmaceutical CompanysupportingStrategic or Co-development PartnerCo-sponsored hepatitis training course 'Basic Knowledge on Diagnosis and Treatment of Viral Hepatitis' for young doctors and healthcare professionals in Ho Chi Minh City.

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• POLYVAC: Vietnamese vaccine producer (also state-owned); comparable to Nanogen as a domestic manufacturer of vaccines and biologicals competing for Vietnamese MOH contracts and exporting regionally.
• Hetero Drugs: India-based generic and biosimilar manufacturer with WHO-prequalified vaccine capabilities and international export model; comparable on cost-driven biologics manufacturing and emerging-market export strategy.
• Shanghai Henlius Biotech: Chinese biosimilar specialist with a portfolio of mAb biosimilars (rituximab, trastuzumab); comparable to Nanogen as an Asia-based CHO biosimilar manufacturer targeting affordable biologics export markets.
• VABIOTECH (Vaccine and Biological Production Company No. 1): Vietnamese state-owned vaccine manufacturer; directly comparable as a domestically-developed biologic (vaccine) producer in Vietnam, sharing the same regulatory environment, customer base (government immunization programs), and strategic positioning around national vaccine self-sufficiency.

Broad incumbents

• Celltrion: Korean biosimilar leader with global commercialization of mAb biosimilars (Remsima etc.); comparable as a CHO-based biosimilar manufacturer with global export footprint that competes with Nanogen on cost-driven biosimilar economics.
• Dr. Reddy's Laboratories: India-headquartered pharma major with biosimilars, vaccines, and CMO services; comparable as a vertically-integrated producer that competes with Nanogen on hepatitis therapeutics and contract manufacturing.
• LG Chem Life Sciences: Korean conglomerate's biopharma arm with vaccines, biologics and CMO services; comparable as a regional player combining biologics manufacturing with CMO/contract services for global pharma.

Emerging players

• Biocon: India-based biopharmaceutical company with biosimilars and CHO-based biologics manufacturing; comparable as a low-cost biosimilar producer and emerging Asian biologic manufacturer with hepatitis and oncology pipelines.
• Samsung Bioepis: Korean biosimilar developer focused on mAb biosimilars (etanercept, infliximab, etc.); comparable as a CHO-based biosimilar specialist targeting affordable access markets.

Others

• Syngene International: India-based CRO/CDMO with biologics manufacturing services; comparable as a contract development and manufacturing partner serving global pharma with biologics capabilities — analogous to Nanogen's CMO service offering.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/nanogen-pharmaceutical-biotechnology-co-ltd-

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanogen Pharmaceutical Biotechnology Joint Stock Company